Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks

Depressive Disorder ◽

Elderly Patients ◽

Oral Administration ◽

Multicentre Study ◽

Treatment Period ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

International Clinical Psychopharmacology ◽

10.1097/yic.0b013e3283542457 ◽

2012 ◽

Vol 27 (4) ◽

pp. 215-223 ◽

Cited By ~ 233

Author(s):

Cornelius Katona ◽

Thomas Hansen ◽

Christina Kurre Olsen

Keyword(s):

Depressive Disorder ◽

Elderly Patients ◽

Fixed Dose ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study

Psychopharmacology ◽

10.1007/s00213-010-1822-y ◽

2010 ◽

Vol 213 (2-3) ◽

pp. 639-646 ◽

Cited By ~ 10

Author(s):

Jian-Jun Ou ◽

Guang-Lei Xun ◽

Ren-Rong Wu ◽

Le-Hua Li ◽

Mao-Sheng Fang ◽

...

Keyword(s):

Depressive Disorder ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Dose Study ◽

Efficacy of agomelatine given orally on improvement of subjective sleep in patients with major depressive disorder: a randomised, double-blind, flexible-dose international multicentre study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI) twelve week treatment plus double-blind extension for 12 weeks

http://isrctn.org/> ◽

10.1186/isrctn55250367 ◽

2013 ◽

Author(s):

Emmanuelle Corruble

Keyword(s):

Depressive Disorder ◽

Multicentre Study ◽

Selective Serotonin Reuptake Inhibitor ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Major Depressive ◽

Double Blind ◽

Subjective Sleep ◽

Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks

http://isrctn.org/> ◽

10.1186/isrctn38378163 ◽

2012 ◽

Author(s):

Frédéric Rouillon

Keyword(s):

Depressive Disorder ◽

Treatment Period ◽

Fixed Dose ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial

Pharmacology ◽

10.1159/000368559 ◽

2014 ◽

Vol 94 (5-6) ◽

pp. 199-206 ◽

Cited By ~ 7

Author(s):

Lin Zhang ◽

Wei-Wei Xie ◽

Le-Hua Li ◽

Hong-Geng Zhang ◽

Gang Wang ◽

...

Keyword(s):

Depressive Disorder ◽

Prolonged Release ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Dose Trial ◽

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Erratum: A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Neuropsychopharmacology ◽

10.1038/npp.2016.181 ◽

2016 ◽

Vol 41 (12) ◽

pp. 2961-2961 ◽

Cited By ~ 4

Author(s):

Atul R Mahableshwarkar ◽

John Zajecka ◽

William Jacobson ◽

Yinzhong Chen ◽

Richard SE Keefe

Keyword(s):

Cognitive Function ◽

Depressive Disorder ◽

Major Depressive ◽

Double Blind ◽

Dose Study ◽

Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria

Amine Oxidases and Their Impact on Neurobiology ◽

10.1007/978-3-7091-9113-2_26 ◽

1990 ◽

pp. 177-184 ◽

Cited By ~ 1

Author(s):

G. F. Hebenstreit ◽

M. Loidl ◽

U. Baumhackl ◽

B. Gallhofer ◽

Ch. Geretsegger ◽

...

Keyword(s):

Depressive Disorder ◽

Multicenter Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

Journal of Affective Disorders ◽

10.1016/j.jad.2018.02.056 ◽

2018 ◽

Vol 235 ◽

pp. 236-241 ◽

Cited By ~ 16

Author(s):

Somaye Arabzadeh ◽

Elham Hakkikazazi ◽

Nazila Shahmansouri ◽

Abbas Tafakhori ◽

Alireza Ghajar ◽

...

Keyword(s):

Depressive Disorder ◽

Oral Administration ◽

Controlled Trial ◽

Response To Treatment ◽

Major Depressive ◽

A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder

International Clinical Psychopharmacology ◽

10.1097/yic.0000000000000304 ◽

2020 ◽

Vol 35 (3) ◽

pp. 137-146 ◽

Cited By ~ 3

Author(s):

Andrea Fagiolini ◽

Umberto Albert ◽

Laura Ferrando ◽

Erik Herman ◽

Cosmina Muntean ◽

...

Keyword(s):

Depressive Disorder ◽

Extended Release ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Major Depressive ◽